Regeneron provides update on biologics license application for linvoseltamab

Tarrytown, n.y., aug. 20, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) for the biologics license application (bla) for linvoseltamab in relapsed/refractory (r/r) multiple myeloma (mm) that has progressed after at least three prior therapies. this anticipated outcome was previously disclosed during regeneron's second quarter 2024 earnings call.
REGN Ratings Summary
REGN Quant Ranking